Patents by Inventor Vassilios Papadopoulos

Vassilios Papadopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301357
    Abstract: The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 28, 2019
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Vassilios Papadopoulos, Yasaman Aghazadeh, Jinjiang Fan
  • Publication number: 20160108087
    Abstract: The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
    Type: Application
    Filed: May 21, 2014
    Publication date: April 21, 2016
    Inventors: Vassilios Papadopoulos, Yasaman Aghazadeh, Jinjiang Fan
  • Patent number: 8216798
    Abstract: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 10, 2012
    Assignee: Georgetown University
    Inventors: Vassilios Papadopoulos, Thierry Hauet
  • Publication number: 20110081295
    Abstract: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.
    Type: Application
    Filed: October 1, 2010
    Publication date: April 7, 2011
    Applicant: Georgetown University
    Inventors: VASSILIOS PAPADOPOULOS, THIERRY HAUET
  • Patent number: 7863010
    Abstract: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 4, 2011
    Assignee: Georgetown University
    Inventors: Vassilios Papadopoulos, Thierry Hauet
  • Publication number: 20100015114
    Abstract: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 21, 2010
    Applicant: Georgetown University
    Inventors: Vassilios PAPADOPOULOS, Thierry HAUET
  • Publication number: 20090286876
    Abstract: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of ? amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 12, 2008
    Publication date: November 19, 2009
    Inventors: Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos
  • Patent number: 7615355
    Abstract: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: November 10, 2009
    Assignee: Georgetown University
    Inventors: Vassilios Papadopoulos, Thierry Hauet
  • Publication number: 20090197891
    Abstract: The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of ? amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 12, 2005
    Publication date: August 6, 2009
    Inventors: Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos
  • Publication number: 20090176802
    Abstract: A novel method for treating a mammal exposed to an exogenous neurotoxic agent is disclosed.
    Type: Application
    Filed: July 30, 2008
    Publication date: July 9, 2009
    Inventors: Vassilios Papadopoulos, Laurent Lecanu, Janet Greeson
  • Publication number: 20080194619
    Abstract: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylquinuclidine derivative that inhibits pathogenic infectivity, including pharmaceutically acceptable salts
    Type: Application
    Filed: April 1, 2005
    Publication date: August 14, 2008
    Inventors: Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos
  • Publication number: 20070269539
    Abstract: The invention features methods for treating neurotoxicity associated with therapeutic agents, e.g., chemotherapeutic agents, and compositions and kits for use therein. The methods employ an extract of Ginkgo biloba to mitigate the neurotoxic effects of the therapeutic agents.
    Type: Application
    Filed: May 3, 2004
    Publication date: November 22, 2007
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: John Marshall, Vassilios Papadopoulos
  • Patent number: 7267977
    Abstract: The expression and subcellular localization of peripheral-type benzodiazepine receptors (PBR) is shown in this application to correlate with the metastatic potential of cells, and increased cell proliferation. Inhibition of PBR expression, function or stability results in a decrease in cell proliferation. Compositions and methods for regulating and/or monitoring PBR and its expression are useful for the detection, diagnosis, prognosis and treatment of solid tumors, in particular, breast cancer.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: September 11, 2007
    Assignee: Georgetown University
    Inventors: Vassilios Papadopoulos, Martine Culty
  • Publication number: 20070049585
    Abstract: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of procaine, procainamide or an analog thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 14, 2006
    Publication date: March 1, 2007
    Inventors: Vassilios Papadopoulos, Janet Greeson, Laurent Lecanu
  • Publication number: 20060247248
    Abstract: A novel compound and method for preventing or treating neurodegenerative diseases by inhibiting acetylcholinesterase and binding the sigma-1 receptor are disclosed. Dimethylcarbamic acid 2,3-bis-dimethylcarbamoyloxy-6-[4-(4-ethyl-piperazin-yl)-butyryl]-phenyl ester and its derivatives represent a novel therapeutic strategy against ?-amyloid peptide induced neurotoxicity, in inhibiting acetylcholinesterase, in improving cholinergic transmission, in binding the sigma-1 receptor, and in releasing a metabolite that is active both as a sigma-1 receptor ligand and an antioxidant.
    Type: Application
    Filed: February 3, 2006
    Publication date: November 2, 2006
    Inventors: Vassilios Papadopoulos, Laurent Lecanu, Janet Greeson
  • Publication number: 20060194814
    Abstract: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 2, 2005
    Publication date: August 31, 2006
    Inventors: Vassilios Papadopoulos, Janet Greeson, Laurent Lecanu
  • Publication number: 20060194815
    Abstract: The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome.
    Type: Application
    Filed: December 2, 2005
    Publication date: August 31, 2006
    Inventors: Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos, Jing Xu
  • Publication number: 20060182821
    Abstract: The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine_receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell.
    Type: Application
    Filed: April 17, 2006
    Publication date: August 17, 2006
    Inventors: Katy Drieu, Vassilios Papadopoulos
  • Publication number: 20060167108
    Abstract: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of ? amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 2, 2005
    Publication date: July 27, 2006
    Inventors: Laurent Lecanu, Janet Greeson, Vassilios Papadopoulos
  • Patent number: 7078434
    Abstract: The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: July 18, 2006
    Assignees: Societe de Conseils de Recherches et d'Applications Scientifiques SAS, Georgetown University
    Inventors: Katy Drieu, Vassilios Papadopoulos